Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobac...(bans. This is not an ill tasting lozenge...),Health

Joseph Fuisz, continued: "It is important to understand that the Fuisz Tobacco strip's super bioavailability is used to lower the amount of tobacco contained in our smokeless product, and not to develop ever-higher nicotine plasma concentrations. The Fuisz tobacco strip offers not only excellent tobacco satisfaction but is a great tasting product that appeals greatly to the vast majority of adult smokers, most of whom are not inclined to use existing smokeless tobacco products."

The clinical study was performed by an independent contract research organization that serves the pharmaceutical industry.

The Fuisz Tobacco smokeless tobacco product is a tobacco containing sheet, similar in appearance to a Listerine(R) PocketPak(R) breath strip but substantially thicker and taking longer to dissolve. The Fuisz Tobacco strip is spitless and dissolves entirely in the cheek. This means that the product can be discretely consumed in a social setting without residue to remove from the mouth after use -- unlike traditional smokeless tobacco products. Fuisz Tobacco's tobacco strip technology is protected by multiple patents pending and licenses.

Fuisz Tobacco is a private company. Its founding partner, Richard C. Fuisz, M.D., is a noted pharmaceutical inventor, including in the thin film drug delivery, quick dissolve tablet, taste masking and controlled release fields (http://www.en.wikipedia.org/wiki/Richard_Fuisz). Fuisz Tobacco's managing partner, Joseph Fuisz, is a corporate lawyer and is a named inventor on over forty thin film drug delivery patents issued and pending. Mr. Fuisz previously served as Senior Vice President for Busines
'/>"/>